4月13日 - ** 药物开发商Allogene Therapeutics ALLO.O股价盘前大涨57%至4.2美元
** 该公司称 (link)，一项中期研究显示，其实验性CAR-T疗法降低了血癌患者癌症复发的风险
** 该公司正在大 B 细胞淋巴瘤患者中测试这种被称为 cema-cel 的药物，这些患者在初次治疗后癌症复发的风险很高。
** Cema-cel 使用来自健康捐献者的白细胞，特别是 T 细胞来治疗这种疾病
** ALLO 公司股票今年累计上涨 98.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.